Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

Endocrinology

Volumn 144, Issue 3, 2003, Pages 1032-1044

  Knowlden, Janice M ^a   Hutcheson, Iain R ^a   Jones, Helen E ^a   Madden, Tracieann ^a   Gee, Julia M W ^a   Harper, Maureen E ^a   Barrow, Denise ^a   Wakeling, Alan E ^b   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; LIGAND; M PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHOPROTEIN; RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DIMERIZATION; DRUG RESISTANCE; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; ONCOGENE C ERB; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; DIMERIZATION; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA, MESSENGER; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 0037373326     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-220620     Document Type: Article

References (61)

1. Howell A, Defriend D, Anderson E 1993 Mechanisms of response and resistance to endocrine therapy for breast cancer and the development of new treatments. Rev Endocr Relat Cancer 43:5-21
2. Osborne CK, Fuqua SA 1994 Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 32:49-55
3. Clarke R, Leonessa F, Welch JN, Skaar TC 2001 Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71
4. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SAW, Osborne CK 1993 Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26:237-246
5. Brunner N, Frandesen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R 1993 MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53:3229-3232
6. Lykkesfeldt AE, Mogens MW, Briand P 1994 Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAM R-1. Cancer Res 54:1587-1595
7. Robertson JF 1996 Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 73:5-12
8. Nicholson RI, McClelland RA, Robertson JFR, Gee JMW 1999 Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6:373-387
9. Nicholson RI, Gee JMW 2000 Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 82:501-513
10. Salomon DS, Bradt R, Ciardiello F, Normanno N 1995 Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
11. Nicholson RI, Gee JMW, Jones H, Harper ME, Wakeling AE, Willsher P, Robertson JFR 1997 EGF receptor in tumor growth and progression. Heidelberg, Germany: Springer-Verlag; 105-128
12. Favoni RE, De Cupis A 2000 The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol Rev 52:179-206
13. Olayioye MA, Neve RM, Lane HA, Hynes N 2000 The erbB signaling network: receptor heterodimerization in development and cancer. The EMBO J 19:3159-3167
14. Daly RJ 1999 Take your partners, please-signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors 16:255-263
15. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH 1992 Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121
16. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW 1993 Relationship between EGF-R, c-erbB2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A:1018-1023
17. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW 1994 Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy. Breast Cancer Res Treat 29:117-125
18. van Agthoven TT, van Agthoven TL, Portengen H, Foekens JA, Dorssers LC 1992 Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52:5082-5088
19. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK 1992 Estrogen-dependent tamoxifen-resistant tumorigenic growth of MCF7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95
20. Miller DL, El-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG 1994 Emergence of MCF7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ 5:1263-1274
21. Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG 1995 MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117
22. Kurokawa H, Lenferink AEG, Simpson JF, Piscane PI, Sliwkowski MX, Forbes JT, Arteaga CL 2000 Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60:5887-5894
23. Long B, McKibben BM, Lynch M, van den Berg HW 1992 Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br J Cancer 65:865-869
24. El-Zarruk AA, van den Berg HW 1999 The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase. Cancer Lett 142:185-193
25. McClelland RA, Barrow D, Madden T, Dutkowski CM, Pamment J, Knowlden J, Gee JM, Nicholson RI 2001 Enhanced epidermal growth factor receptor signalling in MCF7 breast cancer cells following long-term culture in the presence of the pure antioestrogen ICI 182,780 (Faslodex). Endocrinology 142:2776-2788
26. Ullrich A, Schlessinger J 1990 Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212
27. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U 2000 Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer (Pred Oncol) 89:384-388
28. Gee JMW, Robertson JFR, Ellis IO, Nicholson RI 2001 Phosphorylation of ERK1/2 mitogen activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95:247-254
29. El-Ashry D, Miller DL, Kharbanda S, Lippman ME, Kern FG 1997 Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15:423-435
30. Donovan JCH, Milic A, Slingerland JM 2001 Constitutive MEK/MAPK activation leads to p27Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 276:40888-40895
31. Courts AS, Murphy LC 1998 Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 58:4071-4074
32. Shim W-S, Conaway M, Masamura S, Yue W, Wang JP, Kmar R, Santen RJ 2000 Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141:396-405
33. Baselga J, Averbuch SD 2000 ZD1839 ('Iressa') as an anticancer agent. Drugs 60:33-40
34. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR 1995 A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92:7686-7689
35. Baselga J, Albanell J, Molina MA, Arribas J 2001 Mechanism of action of trastuzumab and scientific update. Semin Oncol 5(Suppl 16):4-11
36. Beerli RR, Hynes NE 1996 Epidermal growth factor-related peptides activate distinct subsets of erbB receptors and differ in their biological activities. J Biol Chem 271:6071-6076
37. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J 2002 Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124
38. Willsher PC, Pinder SE, Gee JM, Ellis IO, Chan SY, Nicholson RI, Blamey RW, Robertson JF 1998 C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. Anticancer Res 18:3695-3698
39. Knowlden JM, Gee JM, Seery LT, Farrow L, Gullick WJ, Ellis IO, Blamey RW, Robertson JF, Nicholson RI 1998 c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17:1949-1957
40. McClelland RA, Gee JM, Francis AB, Robertson JF, Blamey RW, Wakeling AE, Nicholson RI 1996 Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-α protein expression in human breast cancer. Eur J Cancer 32A:413-416
41. Rajkumar T, Gooden CS, Lemoine NR, Gullick WJ, Gooden CS 1993 Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1. J Pathol 170:271-278
42. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI 1994 Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59:619-628
43. Knowlden JM, Gee JM, Bryant S, McClelland RA, Manning DL, Mansel R, Ellis IO, Blamey RW, Robertson JF, Nicholson RI 1997 Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. Clin Cancer Res 3:2165-2172
44. Sambrook J, Fritsh EF, Maniatis T 1989 Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press
45. Hutcheson IR, Knowlden JM, Barrow D, Jones HE, Gee JMW, Nicholson RI 2001 The novel ER down-regulator, Faslodex, modulates EGFR/MAPK activity in tamoxifen-resistant MCF-7 breast cancer cells. Clin Cancer Res 7:557
46. Larsen SS, Egebald M, Jaattela M, Lykkesfeldt AE 1999 Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. Breast Cancer Res Treat 58:41-56
47. DeFazio A, Chiew Y-E, Sini RL, Janes PW, Sutherland RL 2000 Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 87:487-498
48. Rajkumar T, Gullick WJ 1994 The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 29:3-9
49. Sorkin A, Waters CM 1993 Endocytosis of growth factor receptors. Bioessays 15:375-382
50. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G 1996 All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271:5251-5257
51. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y 1998 Differential endocytic routing of homo-and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17:3385-3397
52. Keshamouni VG, Mattingly RR, Reddy KB 2002 Mechardsm of 17-β-estradiol-induced Erk1/2 activation in breast cancer cells: a role for HER2 and PKC-δ. J Biol Chem 277:22558-22565
53. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y 1996 A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287
54. Graus-Porta D, Beerli RR, Daly JM, Hynes NE 1997 ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655
55. Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI 1989 Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58:287-292
56. Dougall WC, Qian X, Greene MI 1993 Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. J Cell Biochem 53:61-73
57. van Agthoven T, van Agthoven TL, Dekker A, Foekens JA, Dorssers LC 1994 Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol Endocrinol 8:1474-1483
58. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL III 1994 Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91:8132-8136
59. Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R 1996 Involvement of heregulin-β2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 56:3350-3358
60. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW 1994 Transforming growth factor-α and endocrine sensitivity in breast cancer. Cancer Res 54:1684-1689
61. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL 2001 Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895